Senthil Damodaran, MD, PhD, is currently an Assistant Professor in Breast Medical Oncology with a joint appointment in Investigational Cancer Therapeutics at the MD Anderson Cancer Center. His research focuses on 1) genomics-driven clinical trials 2) application of genomics for target discovery in breast cancers, and 3) characterization of secondary drug resistance mechanisms. He is currently leading the efforts for clinical application of genomics in metastatic breast cancers as well as the TNBC Moon Shots Program at MD Anderson. He is the PI of NCI-MATCH sub-protocol Z1F, phase II study of copanlisib in patients with tumors with PIK3CA mutations, and the INTERACT study, which employs real-time ctDNA monitoring to identify secondary ESR1 alterations in HR positive MBC and evaluates if early intervention with genomically targeted agent can improve outcomes. Additionally, he also serves as co-PI for multiple early phase targeted therapy trials in TN and ER positive MBC.